STOCKHOLM, May 9, 2022 /PRNewswire/ — RaySearch Laboratories AB (publ) is pleased to announce an agreement to collaborate with GE Healthcare, a global leader in medical devices, diagnostics and digital solutions, to develop a new radiation therapy simulation and treatment planning workflow solution that incorporates the latest advances in treatment planning technology.
The companies intend to combine RaySearch’s advanced treatment planning system, RayStation®* GE Healthcare‘s leading multimodality (CT/MR/molecular imaging) simulation systems to make cancer treatment faster and more precise.
According to the US National Institutes of Health, more than 60 percent of cancer patients undergo radiation therapy1, which requires high-quality imaging to precisely target tumors while sparing healthy tissue. Accurate imaging is fundamental to determining the size, shape and characteristics of tumors and distinguishing between healthy tissue. A key issue for oncologists can be the cumbersome simulation process and the need to manually navigate multiple systems and workflows. The aim of the collaboration is to simplify this process by enabling point-of-care decisions in the simulation space.
GE Healthcare and RaySearch aim to enable hospitals and cancer treatment centers to implement an interoperable and integrated workflow that optimizes their clinical planning and operational outcomes. As providers seek to automate radiation oncology processes in light of the increasing patient population and advances in delivery of radiation treatments, GE and RaySearch are working to bring complementary technologies and solutions together to drive innovation and support the radiation oncology community.
Jan Makela, President & CEO, Imaging, GE Healthcare, said, “GE Healthcare is excited to partner with RaySearch as we strive to improve precision guidance in radiation therapy planning and treatment. Cancer care can only be improved when everyone involved works together and this is one of several partnerships we seek to benefit caregivers and patients. Clinicians tell us that navigating multiple systems to get a clear picture of where cancer cells are is one of their biggest problems. We are working to achieve this by collaborating with complementary solutions and technologies along the radiotherapy treatment pathway to help.”
Johan Löf, Founder and CEO of RaySearch Laboratories, says: “Software has tremendous potential and is now the driving force for innovation in oncology. We are thrilled to be collaborating with a partner on the scale of GE Healthcare, one of the largest providers of precision medicine, to bring scientific advances to the clinical world. Our solutions are already supporting thousands of clinics worldwide in the fight against cancer.”
About GE Healthcare
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As the world’s leading innovator in medical technology, pharmaceutical diagnostics and digital solutions, GE Healthcare enables physicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services powered by its Edison Intelligence platform. With over 100 years of healthcare industry experience and approximately 48,000 employees worldwide, the company operates at the center of an ecosystem working towards precise health, digitizing healthcare, increasing productivity and driving outcomes for patients, providers, healthcare systems and researchers around the world improved.
RaySearch Laboratories AB (publ) is a medical technology company developing innovative software solutions for improved cancer care. RaySearch sells the treatment planning system (TPS) RayStation®* and the oncology information system (OIS) RayCare®*. The latest additions to the RaySearch product line are RayIntelligence® and RayCommand®. RayIntelligence is an oncology analysis system (OAS) that enables cancer clinics to collect, structure and analyze data. RayCommand, a Treatment Control System (TCS), is designed to connect the treatment device to the treatment planning and oncology information systems.
RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the stock has been listed on Nasdaq Stockholm since 2003. For more information, see raysearchlabs.com.
RayStation®* is a flexible, innovative treatment planning system chosen by many of the world’s leading cancer centers. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading treatment plan optimization algorithms for HDR brachytherapy and external beam beam therapy using photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment devices, providing a control center for all treatment planning needs and ensuring centers get more value from existing equipment. RayStation also integrates seamlessly with RayCare®*. By harmonizing treatment planning, the care of cancer patients will be improved worldwide.
1. NIH National Cancer Institute, Radiation Therapy and You: Support for People with Cancer, NIH Publication #17-7157, October 2016.
* Subject to regulatory approval in some markets.
Johan Löf, Founder and CEO, RaySearch Laboratories AB (ed.)
Telephone: +46 (0)8 510 530 00, [email protected]
Björn Hårdemark, Interim CFO, RaySearch Laboratories AB (ed.)
Telephone: +46 (0)709 564 217, [email protected]
This information was provided to you by Cision http://news.cision.com
The following files are available for download:
SOURCE RaySearch Laboratories
Company codes: Bloomberg:[email protected], ISIN:SE0000135485, RICS:RAYB.ST, Stockholm:RAY-B